Novo Nordisk stock
Price history
−10.22% over the period1 year: from kr 312.70 (November 17, 2025) to kr 280.75 (November 17, 2026), −10.22%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | kr 280.75 |
| October 30, 2026 | kr 266.10 |
| September 30, 2026 | kr 253.20 |
| August 31, 2026 | kr 292.40 |
| July 31, 2026 | kr 306.50 |
| June 30, 2026 | kr 314.60 |
| May 29, 2026 | kr 292.95 |
| April 30, 2026 | kr 272.25 |
| March 31, 2026 | kr 230.90 |
| February 27, 2026 | kr 237.90 |
| January 30, 2026 | kr 369.55 |
| December 30, 2025 | kr 325.25 |
| November 28, 2025 | kr 317.00 |
| November 17, 2025 | kr 312.70 |
At a glance
The company
Researches, develops, manufactures and distributes pharmaceutical products for obesity, diabetes, rare diseases and other therapeutic areas
Latest results
Quarter to September 30, 2026 · EPS kr 5.79 (estimate kr 4.69)
Next event
TickerLandia's take on Novo Nordisk
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 12 vs a median of 24 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 11 vs 21 (−48%) in a group of 10.
- Strong point: Profitability (92/100 in its group). Weak point: Market momentum (33/100).
- “Best dividend stocks” (Denmark): No. 1 of 1.
- “Below historical valuation” (Denmark): No. 2 of 4.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−32.80% from the 52-week high
Analysts · 26 analysts
Average targetkr 299.91+8.86% vs. price
Buy 5 · Hold 15 · Sell 6 · Hold
TickerLandia Fingerprint: Novo Nordisk
Compared with similar companies: very high profitability.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow32
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 10.9 2 Price/sales 3.68 54 Forward P/E 12.2 31 EV/EBITDA 7.25 10 Price/book 5.64 60 Profitabilityvery high92
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 83.3% 94 Net margin 33.9% 94 ROE 58.4% 90 ROA 19.1% 90 Operating margin 50.8% 94 Earnings stabilityhigh68
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.3% 82 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthaverage49
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +20.43% 94 Revenue growth (year over year) +5.60% 30 Earnings growth (year over year) −15.80% 23 Financial strengthaverage50
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.68 70 Interest coverage 33.4 70 Debt/equitycounts in reverse: lower means more financial strength 0.62 56 Current ratio 0.85 2 Dividendaverage53
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 26 years 38 Payout ratio 45.9% 35 Dividend yield 4.2% 85 Market momentumweak33
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −8.29% 20 Distance from 200-day average +1.25% 45 Riskhigh80
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 43.1% 90 Volatility (60 days) 32.8% 70
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Novo Nordisk is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Novo Nordisk's P/E today is 12.2, below the median of its last 10 fiscal years (23.6; between 14.1 and 38.4 from 2016 to 2025). Novo Nordisk's P/E (trailing 12 months): 11.2, −48% against the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | Novo Nordisk | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 11.2 | Low | |
| Forward P/E | 12.5 | Middle | |
| Operating margin | 50.8% | High | |
| ROE | 58.4% | High | |
| Debt/equity | 0.62 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Novo Nordisk. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 79.2B
Latest quarter · Q3 2026
Net income
kr 16.74B
Latest quarter · Q3 2026
Quarterly net margin
21.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- kr 1.26T
- P/E
- 11.2
- EPS
- kr 25.49
- Volume
- 4.61M
- Daily trading
- €189.57M
- Dividend yield
- 4.25%
- Last ex-dividend on August 14, 2026
How Novo Nordisk is changing
All resultsRevenue grew 19.5% a year on average over the last 5 years
Operating margin rose from 42.7% to 45.5%
Free cash flow equal to 75% of net income
Returns
Novo Nordisk returns with dividends
kr 1,000 invested in Novo Nordisk 5 years ago, on November 17, 2021, would be worth kr 835 today with dividends reinvested: −16.55% in total, −3.55% per year. On price alone it would be kr 745 (−25.49%).
| Period | Novo Nordisk | kr 1,000 becomes |
|---|---|---|
| 1 month | +9.45% | kr 1,095 |
| 6 months | −7.92% | kr 921 |
| Year to date | −13.68% | kr 863 |
| 1 year | −5.91% | kr 941 |
| 3 years | −55.94% | kr 441 |
| 5 years | −16.55% | kr 835 |
| 10 years | +208.73% | kr 3,087 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Novo Nordisk: technical analysis
Novo Nordisk shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 73.2% below its all-time closing high (kr 1,028.00, June 25, 2024).
- Trend
- No clear trend
- RSI (14 sessions)
- 55
- Between 30 and 70
- vs 200-session average
- −2.04%
Support and resistance
Price areas where Novo Nordisk has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 297.25+7.89%3 touches, last on May 29, 2026
- Resistancekr 287.35+4.30%5 touches, last on November 4, 2026
- Resistancekr 277.88+0.86%2 touches, last on June 18, 2026
- Last pricekr 275.50
- Supportkr 265.38−3.68%4 touches, last on October 22, 2026
- Supportkr 255.30−7.33%2 touches, last on October 29, 2026
- Supportkr 244.72−11.17%3 touches, last on October 5, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 32.9%
- Largest fall in the last year
- −43.07%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Novo Nordisk: seasonality
Average monthly price change over 26 years
Over the last 26 years, the strongest month for Novo Nordisk has been April: +17.18% on average, positive in 19 years out of 26. The weakest has been September: −1.88% on average, positive in 10 years out of 26. November, the current month, has been positive in 19 years out of 25 (+2.80% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.01% | +0.53% | 13 of 25 |
| February | +2.90% | +4.90% | 19 of 26 |
| March | +0.69% | −0.11% | 12 of 26 |
| April | +17.18% | +3.00% | 19 of 26 |
| May | +0.78% | +1.74% | 16 of 26 |
| June | +2.56% | +2.63% | 15 of 26 |
| July | −0.94% | −1.02% | 10 of 26 |
| August | +2.41% | +1.64% | 14 of 26 |
| September | −1.88% | −1.22% | 10 of 26 |
| October | +0.48% | +0.95% | 15 of 26 |
| November | +2.80% | +2.23% | 19 of 25 |
| December | +1.07% | +1.66% | 20 of 25 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Novo Nordisk and its competitors
Employing 68,794 people, Novo Nordisk develops, manufactures and sells medicines, with diabetes care, weight management and rare diseases at the core of its portfolio. Products include insulin pens, some with digital dose-guidance features, growth hormone pens, injection needles and the Wegovy pill, an oral treatment for weight management. Customers are reached in Europe, North America, Japan, Korea, Oceania, Southeast Asia, China, Hong Kong, Taiwan, Latin America, the Middle East and Africa.
- Headquarters
- Bagsvaerd, Denmark
- Employees
- 68,794
- Founded
- 1923
- Chief executive
- Maziar Doustdar
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Novo NordiskNOVO.B | $184.87B | 50.8% | 11.2 | −7.92% |
| SanofiSAN | $116.52B | 22.3% | 25.5 | +17.04% |
| AstraZenecaAZN | $287.12B | 25.8% | 26.6 | +1.25% |
| NovartisNOVN | $305.16B | 34.0% | 32.6 | +14.23% |
| GSKGSK | $102.04B | 30.5% | 18.0 | +0.35% |
| Roche HoldingROP | $387.48B | 33.1% | 26.7 | +25.84% |
Same industry or related industries, similar size. Compare Novo Nordisk with its competitors · Full profile
